Drug discovery is a data-driven research process that requires accurate data capture, ample and reliable data storage, and real-time data analysis. Timely access to all compound data is essential for optimal decision-making, while rapid and seamless registration is crucial to protecting your investment.
See how the integration of two platforms, Certara D360 and Scilligence ELN/LIMS, enables scientists to swiftly travel from “data in” (substance, assay, and inventory data) to “data out” (self-service queries and analytics) along a path that includes entity registration. Two product leaders and scientists, David Lowis of D360 and Alan Olague of Scilligence, will briefly outline the challenges that discovery chemists face in gaining a view that spans the DMTA cycle. Steve Unger, Department Head and Director of Informatics at Pliant Therapeutics, will then present the technological solutions he’s deployed using D360 for queries and Scilligence tools such as ELN and RegMol. Steve will share essential features and solutions, including combined views of molecule activity and selectivity, and explain why “smart SAR” conducted by a well-equipped chemist still outpaces AI!
Speakers:
Steve Unger
Department Head and Director of Informatics
Pliant Therapeutics
David Lowis
Executive Director, Science Informatics
Certara
Alan Olague
Director of Sales and Marketing
Scilligence